ARL67156 trisodium hydrate FPL 67156 trisodium hydrate|西域试剂

ARL67156 trisodium hydrate FPL 67156 trisodium hydrate,99.0%

产品编号：Bellancom-103265B| 分子式：C₁₅H₂₃Br₂N₅Na₃O₁₃P₃| 分子量：834.61

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-103265B		￥1800.00	杭州北京（现货）
Bellancom-103265B		￥6500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ARL67156 trisodium hydrate FPL 67156 trisodium hydrate

产品介绍

ARL67156 (FPL 67156) trisodium hydrate 是一种 ecto-ATPase 抑制剂。ARL67156 trisodium hydrate 是竞争性 NTPDase1 (CD39)，NTPDase3 和 NPP1 抑制剂，K_i 分别为 11，18 和 12 μM。ARL67156 trisodium hydrate 可用于钙化性主动脉瓣疾病、哮喘等疾病的研究。

生物活性

ARL67156 (FPL 67156) trisodium hydrate is a selective ecto-ATPase inhibitor. ARL67156 trisodium hydrate is a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K_is of 11, 18 and 12 μM, respectively. ARL67156 trisodium hydrate can be used in the research of disease like calcific aortic valve disease, asthma.

体外研究

ARL67156 trisodium hydrate (1-100 μM) potentiates neurogenic contractions in a concentration-dependent manner^[4].
ARL67156 trisodium hydrate (10 μg/mL, 24 h) increases the surface expression of CXCR3 on ATP-treated HMC-1 cells^[5].
ARL67156 trisodium hydrate (30 μM, 5s) potentiates the norepinephrine release promoted by ATP in guinea pig heart synaptosomes^[6].
ARL67156 trisodium hydrate (100 μM, 4h) significantly decreases HIV-1replication in macrophages^[7].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ARL67156 trisodium hydrate (1.1 μg/kg/day, administered with osmotic pumps implanted subcutaneously, for 28 days) prevents the development of calcific aortic valve disease in Warfarin (HY-B0687)-treated rats.
ARL67156 trisodium hydrate (intraperitoneal injection, 2 mg/kg) prevents the increase of serum adenosine concentration induced by Fructose 1,6-bisphosphate (FBP).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Warfarin-induced mineralization rat model
Dosage:	1.1 μg/kg/day
Administration:	Administered with osmotic pumps implanted subcutaneously, for 28 days
Result:	Prevented the development of aortic stenosis by lowering the level of apoptosis and mineralization of the aortic valve/aorta. Normalized the level of pAkt (an important kinase involved in the survival pathway).

Animal Model:	C57BL/6 mice
Dosage:	2 mg/kg
Administration:	Intraperitoneal injection, 1 h before administration of FBP (100 mg/kg)
Result:	Completely abolished the anti-inflammatory effects of FBP (observed by the neutrophil infiltration, hyperalgesia and oedema of the joint).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Warfarin-induced mineralization rat model
Dosage:	1.1 μg/kg/day
Administration:	Administered with osmotic pumps implanted subcutaneously, for 28 days
Result:	Prevented the development of aortic stenosis by lowering the level of apoptosis and mineralization of the aortic valve/aorta. Normalized the level of pAkt (an important kinase involved in the survival pathway).

Animal Model:	C57BL/6 mice
Dosage:	2 mg/kg
Administration:	Intraperitoneal injection, 1 h before administration of FBP (100 mg/kg)
Result:	Completely abolished the anti-inflammatory effects of FBP (observed by the neutrophil infiltration, hyperalgesia and oedema of the joint).